Login / Signup

Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B.

Natasha Pillay-SmileyJames LeachAdam LaneTrent HummelJason FangusaroPeter M K de Blank
Published in: Cancers (2023)
Treatment with selumetinib did not affect the overall FASI size in children with NF1 treated for progressive low-grade glioma.
Keyphrases
  • low grade
  • signaling pathway
  • high grade
  • young adults
  • lps induced
  • oxidative stress
  • pi k akt
  • nuclear factor
  • multiple sclerosis
  • high intensity
  • newly diagnosed
  • cell proliferation